Stock Analysis
ImmunityBio, Inc. Common StockIBRX
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy10 analystsPrice is 75% of the way from the year's low to its high.
PMP Verdict
Cheap for a reason — weak fundamentals
Risks
- Profitability0
- Quality10
Cheap for a reason — fundamentals remain weak.
Market context
-8.2% today· Z 2.1σ
Bull Case
- ✓Revenue CAGR 231.9% — durable top-line growth
What's happening with IBRX
Profile
profitability, moat, earnings quality, valuation, growth and financial health lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-3.0%)0/25
- P/S (58.6x)0/25
- EV/EBIT (n/a)10/25
- Growth25/100 · Weak
- Revenue CAGR (231.9%)25/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (n/a)0/25
- Net margin (-598.6%)0/25
- Operating margin (-151.9%)0/25
- Financial Health28/100 · Weak
- Altman Z (-6.13)3/25
- Current ratio (5.10)25/25
- Interest coverage (-1.5x)0/25
- Net cash / debt (n/a)0/25
- Quality10/100 · Weak
- Piotroski F (4/9)10/25
- Beneish M (2.45)0/25
- FCF conversion (n/a)0/25
- Margin stability (σ 177907.6%)0/25
- Moat0/100 · Weak
- ROIC >12% years (0/5 yrs)0/25
- Median gross margin (n/a)0/25
- FCF-positive years (0/10 yrs)0/25
- Worst-year net margin (worst -274565.9%)0/25
Risk Flags
- ⚠Altman Z -6.1 — distress-zone balance sheet
- ⚠Beneish M 2.45 — earnings-manipulation flag
- ⚠Negative FCF margin (-1.7%) — burning cash
- ⚠SBC 20.7% of revenue — real dilution cost
- ⚠10 loss-making years in recent history
About ImmunityBio, Inc. Common Stock
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Show more
Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Headquarters: SAN DIEGO, CA · Employees: 691 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-3.0%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -71.9%–-1.7% · 98th pct
P/S (TTM)58.57xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 21.5x–20385.5x · 20th pct
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales71.0xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B RatioNeg. EquityC
Grade C: BuybacksPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-0.11A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROENeg. EquityC
Grade C: BuybacksReturn on Equity. Neg. equity = heavy buybacks
ROA-172.9%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-598.6%D
Grade D: LowNet Income / Revenue
Operating Margin-151.9%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin99.3%A
Grade A: PremiumGross Profit / Revenue
FCF Margin-173.7%D
Grade D: LowFCF / Revenue
True FCF Margin-194.4%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
25ERevenue CAGR231.9%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue20.7%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
28EAltman Z-Score-6.13D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio5.10xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio5.36xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-1.5xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity—
Debt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
10EPiotroski F-Score4/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score2.45D
Grade D: RiskyEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability177907.6%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue4.2%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.29xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Simon Barry J. Filed | Simon Barry J. | SellOpen market sale | -25000 | |
Cohen Cheryl Filed | Cohen Cheryl | Option exercise | -55979 | |
Cohen Cheryl Filed | Cohen Cheryl | SellOpen market sale | -81056 | |
Cohen Cheryl Filed | Cohen Cheryl | Option exercise | +56.0K | |
Cohen Cheryl Filed | Cohen Cheryl | Option exercise | -55979 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Cohen Cheryl Filed | Cohen Cheryl | SellOpen market sale | -131210 | |
Cohen Cheryl Filed | Cohen Cheryl | Option exercise | +56.0K | |
Selecky Christobel Filed | Selecky Christobel | Option exercise | -124414 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years0/5 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)—
Median annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years0/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-274565.9%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$0.34
Cash & short-term investments per share (Finnhub)
Book Value / Share$1.37
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$242.82M
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$-500.47M
Shareholders' equity (book value)
Asset / Liability0.50xD
Grade D: RiskyTotal Assets / Total Liabilities
Market
Market Cap$9.71B
Current Market Capitalization
Beta0.17B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: ImmunityBio, Inc. Common Stock (IBRX)
IBRX is down 8.20% at the last close. Piotroski F-Score of 4/9 indicates mixed fundamentals for ImmunityBio, Inc. Common Stock. Altman Z-Score of -6.13 is below the 1.81 distress threshold — an elevated financial-risk flag. Beneish M-Score of 2.45 is above the −1.78 flag threshold, a signal that reported earnings warrant closer scrutiny. Revenue has compounded at roughly 232% annually — a strong growth profile.
- Free-cash-flow margin is negative (-174%) — the business currently burns cash.
- Interest coverage of -1.5× leaves little room for earnings shocks.
- ImmunityBio, Inc. Common Stock posted a net loss in 10 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 20/100, IBRX trades at a premium to its historical multiples.
See how IBRX ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all IBRX moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 16 | Regular | 9.14 | -8.65% | -2.11 |
| Oct 16 | After-hours | 9.16 | -8.40% | -2.05 |
| Oct 2 | After-hours | 10.29 | +10.88% | 2.24 |
| Sep 23 | Regular | 8.65 | -6.94% | -2.14 |
| Sep 23 | After-hours | 8.63 | -7.11% | -2.19 |
Frequently Asked Questions about IBRX
What is the current ImmunityBio, Inc. Common Stock (IBRX) stock price?
IBRX is trading at $9.18 at the last market close, down 8.20% on the session. PreMarketPrice tracks IBRX pre-market, intraday and after-hours prices.
Is IBRX stock a buy right now?
PreMarketPrice's quantitative model rates ImmunityBio, Inc. Common Stock's financial health at 28/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is IBRX stock overvalued?
ImmunityBio, Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does ImmunityBio, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for IBRX. The Earnings section lists recent reports and updates as dates are announced.
What sector does ImmunityBio, Inc. Common Stock operate in?
ImmunityBio, Inc. Common Stock operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does ImmunityBio, Inc. Common Stock do?
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases.
About ImmunityBio, Inc. Common Stock (IBRX) Stock
ImmunityBio, Inc. Common Stock (IBRX) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, ImmunityBio, Inc. Common Stock is trading at $9.18, down 8.20% on the day with a market capitalization of $9.7 billion. The financial health score for IBRX is 28/100, which indicates poor financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for IBRX stock.
IBRX Stock Analysis & Key Metrics
On PreMarketPrice, you can track ImmunityBio, Inc. Common Stock (IBRX) across multiple dimensions:
- Pre-market price & movement: Real-time IBRX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for IBRX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for ImmunityBio, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 28/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for IBRX.
- Sector peers: Compare IBRX against 5 other healthcare stocks on key financial metrics.
Is IBRX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate ImmunityBio, Inc. Common Stock (IBRX) as an investment. The financial health score of 28/100 suggests poor financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.ImmunityBio, Inc. Common Stock (IBRX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.